Display options
Share it on

Nurs Res Pract. 2013;2013:687519. doi: 10.1155/2013/687519. Epub 2013 Dec 12.

Epigenetic markers of renal function in african americans.

Nursing research and practice

Samantha M Bomotti, Jennifer A Smith, Alicia L Zagel, Jacquelyn Y Taylor, Stephen T Turner, Sharon L R Kardia

Affiliations

  1. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
  2. Department of Epidemiology, School of Public Health, University of Michigan, 1415 Washington Heights, No. 4629, Ann Arbor, MI 48109, USA.
  3. Center for Health Statistics, Washington State Department of Health, Olympia, WA 98501, USA.
  4. School of Nursing, Yale University, New Haven, CT 06477, USA.
  5. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA.

PMID: 24396594 PMCID: PMC3874945 DOI: 10.1155/2013/687519

Abstract

Chronic kidney disease (CKD) is an increasing concern in the United States due to its rapidly rising prevalence, particularly among African Americans. Epigenetic DNA methylation markers are becoming important biomarkers of chronic diseases such as CKD. To better understand how these methylation markers play a role in kidney function, we measured 26,428 DNA methylation sites in 972 African Americans from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. We then evaluated (1) whether epigenetic markers are associated with estimated glomerular filtration rate (eGFR), (2) whether the significantly associated markers are also associated with traditional risk factors and/or novel biomarkers for eGFR, and (3) how much additional variation in eGFR is explained by epigenetic markers beyond established risk factors and biomarkers. The majority of methylation markers most significantly associated with eGFR (24 out of the top 30) appeared to function, at least in part, through pathways related to aging, inflammation, or cholesterol. However, six epigenetic markers were still able to significantly predict eGFR after adjustment for other risk factors. This work shows that epigenetic markers may offer valuable new insight into the complex pathophysiology of CKD in African Americans.

References

  1. Circ Res. 2007 Jun 22;100(12):1686-95 - PubMed
  2. BMC Nephrol. 2008 Aug 05;9:9 - PubMed
  3. Genome Res. 2008 May;18(5):780-90 - PubMed
  4. Kidney Int. 2011 Jan;79(1):23-32 - PubMed
  5. Acta Haematol. 1957 Apr;17(4):237-46 - PubMed
  6. J Intern Med. 2007 May;261(5):488-99 - PubMed
  7. Am J Hum Biol. 2009 Jan-Feb;21(1):2-15 - PubMed
  8. J Am Soc Nephrol. 2008 Nov;19(11):2060-7 - PubMed
  9. Hum Mol Genet. 2011 Nov 1;20(21):4282-9 - PubMed
  10. Nat Rev Endocrinol. 2010 Dec;6(12):665-75 - PubMed
  11. Ann Epidemiol. 2013 Mar;23(3):106-11 - PubMed
  12. Genome Res. 2010 Feb;20(2):170-9 - PubMed
  13. Am J Kidney Dis. 2012 Aug;60(2):241-9 - PubMed
  14. PLoS Med. 2012;9(11):e1001344 - PubMed
  15. Transplantation. 2013 May 27;95(10):1242-8 - PubMed
  16. Ann Clin Biochem. 1998 Sep;35 ( Pt 5):671-3 - PubMed
  17. Annu Rev Pharmacol Toxicol. 2009;49:243-63 - PubMed
  18. Ageing Res Rev. 2009 Oct;8(4):268-76 - PubMed
  19. Trends Mol Med. 2010 Jan;16(1):7-16 - PubMed
  20. Clin J Am Soc Nephrol. 2012 Dec;7(12):1938-46 - PubMed
  21. Nephrol Dial Transplant. 2011 Mar;26(3):920-6 - PubMed
  22. Hum Genet. 2010 Jun;127(6):651-8 - PubMed
  23. Hum Genet. 2013 Sep;132(9):1027-37 - PubMed
  24. PLoS One. 2013 Aug 19;8(8):e73480 - PubMed
  25. J Am Soc Nephrol. 2011 Dec;22(12):2182-5 - PubMed
  26. Annu Rev Med. 2013;64:357-66 - PubMed
  27. Am J Med. 2004 May 15;116(10):676-81 - PubMed
  28. Int J Biochem Cell Biol. 2012 Sep;44(9):1482-90 - PubMed
  29. Hum Mol Genet. 2011 Nov 1;20(21):4268-81 - PubMed
  30. BMC Bioinformatics. 2010 Nov 30;11:587 - PubMed
  31. Epigenetics. 2011 Jan;6(1):20-8 - PubMed
  32. Anticancer Res. 2007 Sep-Oct;27(5A):3051-8 - PubMed
  33. Int J Cancer. 2013 Dec 15;133(12):3008-13 - PubMed
  34. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266 - PubMed

Publication Types

Grant support